Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET in Coral Gables, FL.

A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

About Rallybio

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.

Investor Contacts Samantha Tracy Rallybio Corporation (475) 47-RALLY (Ext. 282) investors@rallybio.com Kevin Lui Precision AQ (212) 698-8691 Kevin.Lui@precisionaq.com Media Victoria Reynolds Mission North (760) 579-2134 rallybio@missionnorth.com

Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 12 2024 まで 1 2025 Rallybioのチャートをもっと見るにはこちらをクリック
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 1 2024 まで 1 2025 Rallybioのチャートをもっと見るにはこちらをクリック